Baillie Gifford & CO Hutchmed (China) LTD Transaction History

Baillie Gifford & CO

$126 Billion
Q2 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 26, 2024	BUY	$16.25 - $20.23 $157,527 - $196,109	9,694 Added 7.17%	144,969 $2.63 Million
Q3 2023 Nov 13, 2023	SELL	$11.85 - $16.95 $85,320 - $122,040	-7,200 Reduced 5.05%	135,275 $2.29 Million
Q2 2023 Jul 28, 2023	SELL	$10.78 - $17.73 $105,105 - $172,867	-9,750 Reduced 6.4%	142,475 $1.71 Million
Q4 2022 Jan 24, 2023	SELL	$7.65 - $15.51 $1.82 Million - $3.69 Million	-237,593 Reduced 60.95%	152,225 $2.25 Million
Q3 2022 Oct 27, 2022	BUY	$8.63 - $15.52 $214,360 - $385,501	24,839 Added 6.81%	389,818 $3.45 Million
Q2 2022 Aug 08, 2022	SELL	$8.59 - $20.77 $6,983 - $16,886	-813 Reduced 0.22%	364,979 $4.61 Million
Q1 2022 May 05, 2022	BUY	$15.52 - $35.65 $26,756 - $61,460	1,724 Added 0.47%	365,792 $6.92 Million
Q4 2021 Jan 20, 2022	SELL	$28.89 - $35.33 $112,584 - $137,681	-3,897 Reduced 1.06%	364,068 $12.8 Million
Q3 2021 Oct 19, 2021	BUY	$35.66 - $42.94 $25,211 - $30,358	707 Added 0.19%	367,965 $13.5 Million
Q2 2021 Aug 02, 2021	BUY	$23.7 - $39.27 $1.05 Million - $1.73 Million	44,105 Added 13.65%	367,258 $14.4 Million
Q1 2021 May 06, 2021	BUY	$27.01 - $36.8 $786,801 - $1.07 Million	29,130 Added 9.91%	323,153 $9.13 Million
Q4 2020 Feb 10, 2021	BUY	$27.51 - $34.36 $616,664 - $770,213	22,416 Added 8.25%	294,023 $9.41 Million
Q3 2020 Nov 12, 2020	BUY	$25.8 - $34.61 $1.15 Million - $1.54 Million	44,567 Added 19.63%	271,607 $8.77 Million
Q2 2020 Aug 12, 2020	BUY	$17.65 - $28.05 $131,227 - $208,551	7,435 Added 3.39%	227,040 $6.26 Million
Q1 2020 May 08, 2020	BUY	$15.19 - $29.51 $25,731 - $49,989	1,694 Added 0.78%	219,605 $3.92 Million
Q2 2019 Aug 08, 2019	SELL	$22.0 - $31.78 $65,670 - $94,863	-2,985 Reduced 1.35%	217,911 $4.79 Million
Q1 2019 May 01, 2019	BUY	$21.27 - $30.58 $466,599 - $670,833	21,937 Added 11.03%	220,896 $0
Q4 2018 Feb 14, 2019	BUY	$23.09 - $37.69 $28,008 - $45,717	1,213 Added 0.61%	198,959 $4.59 Million
Q3 2018 Nov 13, 2018	SELL	$26.55 - $34.38 $183,646 - $237,806	-6,917 Reduced 3.38%	197,746 $6.37 Million
Q2 2018 Jul 17, 2018	SELL	$27.79 - $34.49 $41,045 - $50,941	-1,477 Reduced 0.72%	204,663 $6.17 Million
Q1 2018 May 10, 2018	SELL	$28.87 - $41.13 $9,065 - $12,914	-314 Reduced 0.15%	206,140 $6.09 Million
Q4 2017 Feb 13, 2018	BUY	$27.41 - $39.42 $571,498 - $821,907	20,850 Added 11.23%	206,454 $8.14 Million
Q3 2017 Oct 20, 2017	BUY	$22.15 - $27.5 $399,962 - $496,567	18,057 Added 10.78%	185,604 $5.06 Million
Q2 2017 Aug 10, 2017	BUY	N/A	167,547	167,547 $3.91 Million

Others Institutions Holding HCM

# of Institutions

Shares Held

8.25M

Call Options Held

3.8K

Put Options Held

2.4K

Schroder Investment Management Group London, X0

3.02M
Shares

$54.4 Million
0.06% of portfolio
Allianz Asset Management Gmb H Munich, 2M

1.5M
Shares

$27 Million
0.04% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.15M
Shares

$20.7 Million
0.33% of portfolio
Acadian Asset Management LLC Boston, MA

389K
Shares

$7 Million
0.02% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

358K
Shares

$6.44 Million
0.0% of portfolio

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account